CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells

Chimeric antigen receptor (CAR)-T cells have not made significant progress in the treatment of acute myeloid leukemia (AML) in earlyclinical studies. This lack of progress could be attributed in part to the immunosuppressive microenvironment of AML, such as monocyte-like myeloid-derived suppressor c...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xin Jin, Danni Xie, Rui Sun, Wenyi Lu, Xia Xiao, Yibing Yu, Juanxia Meng, Mingfeng Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2023-12-01
Colecção:	OncoImmunology
Assuntos:	AML CAR-T CD123 immunotherapy NKG2DL
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2248826
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!